Decision-model for treating the anemia of myelodysplastic syndrome (MDS) with Erythropoietin (Epo) + granulocyte colony-stimulating factor (G-CSF).
| Variable . | Value . | Score . | Value . | Score . |
|---|---|---|---|---|
| * Pre-treatment evaluation | ||||
| Predicted response rate: Total score 0 = 74%, 1 = 23%, 2 = 7% | ||||
| Predicted value of model P < 0.001 14 | ||||
| Patients with score 2 do not benefit from treatment with Epo + G-CSF17 | ||||
| Transfusion need* | < 2 U/month | 0 | ≥ 2 U/month | 1 |
| Serum-Epo* | < 500 U/liter | 0 | ≥ 500 U/liter | 1 |
| Variable . | Value . | Score . | Value . | Score . |
|---|---|---|---|---|
| * Pre-treatment evaluation | ||||
| Predicted response rate: Total score 0 = 74%, 1 = 23%, 2 = 7% | ||||
| Predicted value of model P < 0.001 14 | ||||
| Patients with score 2 do not benefit from treatment with Epo + G-CSF17 | ||||
| Transfusion need* | < 2 U/month | 0 | ≥ 2 U/month | 1 |
| Serum-Epo* | < 500 U/liter | 0 | ≥ 500 U/liter | 1 |